Scientific Programme
The Scientific Programme will be available soon!
Topics:
- The basis: immunological pathways of type 2 inflammation
- Eosinophil-associated disorders: asthma, CRSwNPs and EGPA
- Biologicals, eosinophils and tissue remodelling
- Hypereosinophilic syndrome (HES)
- Safety of type 2 biologicals
- Clinical corner: what drives the direction of treatment choice?
- Opportunities to reduce treatment-related burden
- Diagnostic approach to hypereosinophilia
Format of the different activities:
- Sessions: 2-3 lectures around the addressed main topic
- Workshops: The topic will be developed around a clinical case answered by the attendees
- Posters sessions: defended by the delegates
- Oral presentations: defended by the delegates
Attendees will be able:
- to improve their knowledge of immunological basis of local and systemica type 2 inflammation
- to explore the pathogenic and clinical significance of type 2 cytokines in different eosinophil-associated diseases
- to understand the rationale for biologicals’ use in type 2 eosinophil-associated diseases
- to learn how to identify patients affected by different forms of hypereosinophilic syndrome and how to implement the use of biologicals in this condition
- to combine the immunological knowledge with the clinical data collected regarding the safety profile of biologicals targeting eosinophils and type 2 cytokines
- to expand their knowledge about the role of eosinophils in adverse drug reactions
- to actively participate in “clinical corners” by sharing their personal experience in hot topic issues related to type 2 diseases Attendees will be able:
- to improve their knowledge of immunological basis of local and systemica type 2 inflammation
- to explore the pathogenic and clinical significance of type 2 cytokines in different eosinophil-associated diseases
- to understand the rationale for biologicals’ use in type 2 eosinophil-associated diseases
- to learn how to identify patients affected by different forms of hypereosinophilic syndrome and how to implement the use of biologicals in this condition
- to combine the immunological knowledge with the clinical data collected regarding the safety profile of biologicals targeting eosinophils and type 2 cytokines
- to expand their knowledge about the role of eosinophils in adverse drug reactions
- to actively participate in “clinical corners” by sharing their personal experience in hot topic issues related to type 2 diseases